Hepatology Submission Guide: Scope, Format & Tips

A recurring manuscript pattern we see a recurring failure pattern: weak Hepatology submissions often have plausible liver-disease language, but the abstract, model choice, and figures do not prove that the mechanism is liver-specific enough for the AASLD flagship journal.

Evidence boundary: official author instructions tell you what to upload, but they do not tell you whether a hepatocyte-line result, mouse model, cohort size, or cover letter actually clears the liver-specific editorial screen. The submission decision should ask whether the liver biology would still feel central if the disease label were removed from the title.

Hepatology publishes research across the entire spectrum of liver biology and disease. If your work touches liver function, pathology, or treatment, it belongs here. The journal covers viral hepatitis (HBV, HCV, HDV), alcoholic liver disease, NAFLD/NASH, autoimmune liver diseases, liver cancer, transplantation, drug-induced liver injury, and basic hepatocyte biology.

• Research areas that fit:

• Hepatitis B and C virology and treatment

• NAFLD/NASH pathogenesis and therapeutics

• Liver fibrosis mechanisms and reversal

• Hepatocellular carcinoma biology and treatment

• Liver transplantation outcomes and immunology

• Drug hepatotoxicity mechanisms

• Liver regeneration and stem cell biology

• Portal hypertension and cirrhosis complications

• What doesn't belong: Generic inflammation studies that happen to use liver tissue. Broad metabolic papers where liver is just one organ examined. Gallbladder or bile duct research belongs in gastroenterology venues unless there's direct hepatocyte involvement.

The editors filter hard on liver specificity. Your introduction should demonstrate deep knowledge of liver-specific pathways, not general cell biology applied to hepatocytes. Studies using HepG2 cells need strong justification for why this model answers your specific liver question.

• Scope mismatch examples: Papers studying general autophagy that use liver as a convenient model. Broad studies of diabetes complications that mention liver involvement. Generic drug screening in hepatocyte cell lines without liver disease context.

Before you start writing, check recent issues. Notice how every accepted paper positions findings within established liver biology frameworks and connects directly to hepatology practice.

• Word limits: 6,000 words maximum for Original Manuscripts, including references but not the title page, abstract, figure legends, or tables. Review Articles can reach 9,000 words excluding references. Editorials are invited and cap at 1,500 words including references.

• References: Hepatology publishes no separate reference limit for Original Manuscripts, because references count toward the 6,000-word limit. Use AMA style with full page ranges; papers submitted but not yet accepted, personal communications, and unpublished data are not acceptable as listed references.

• Abstract structure is mandatory: Use these exact headings: Background & Aims, Approach & Results, Conclusions. Keep it to 250 words or fewer. Do not use nonstandard abbreviations, references, or footnotes in the abstract.

• Figure specifications:

• No more than 8 figures and tables combined, with a maximum of 6 panels per figure

• Final figures in EPS, TIFF, or MS Office format; halftones at least 300 DPI, combination halftones 600 DPI, line art 1200 DPI

• Authors are charged $500 for each page (whole or partial) of color figures; remove all color from figures and tables to avoid the charge

• Legends go on a separate page at the end of the manuscript document, after the references

• Tables: Tables count toward the combined limit of 8 figures and tables. Upload each table as a separate word-processing document, and don't submit tables as images or photographs.

• Supplementary material rules: Supplemental digital content cannot exceed 10 MB in total per submission. The instructions encourage additional methodological details and nonessential figures there, and references cited in the main text may not be listed only in the supplement. Don't dump borderline results here.

• Statistical requirements: Report actual p values, whether significant or not, and present confidence intervals whenever possible. Describe the statistical methods and specify the software package and version used.

• Human subjects: All human research needs IRB approval mentioned in Methods. Clinical trials require registration numbers. Patient consent must be documented.

• Animal studies: State the care of animal and licensing guidelines under which the study was performed and report in accordance with ARRIVE. For mice and other in vivo models, Hepatology asks for sex and age, genetic background, diet, whether animals were fasted, housing details, and whether interventions were done in the light or dark cycle.

AASLD editors want to see liver expertise immediately. Don't start with generic statements about liver disease importance. Jump straight into what your specific findings add to hepatology knowledge.

• Opening paragraph template: "We report the specific finding in the specific liver disease/model that the specific advancement in understanding. This work addresses the specific gap in current hepatology knowledge and provides the specific clinical or mechanistic insight."

• Second paragraph: Explain why this finding matters to hepatologists specifically. Connect to established liver biology concepts. Reference recent Hepatology papers when relevant.

• Third paragraph: Brief methods overview focusing on liver-specific approaches. Mention if you used novel liver models, patient cohorts, or disease-specific endpoints.

• Fourth paragraph: Significance for the field. How does this change our understanding of liver disease mechanisms or treatment approaches?

• Common cover letter mistakes: Generic disease importance statements. Overselling preliminary findings. Failing to connect to established liver biology. Using phrases like "we believe" instead of stating findings directly.

• What signals expertise: Specific hepatology terminology used correctly. References to established liver disease frameworks. Understanding of current therapeutic challenges in hepatology.

The cover letter often determines whether your paper gets serious editorial attention or quick desk rejection. Cover letter examples specific to liver research can help you avoid common pitfalls.

• Generic inflammation studies: Papers that study general inflammatory pathways but happen to use liver tissue get rejected fast. Hepatology editors want liver-specific mechanisms, not general biology applied to hepatocytes. Your work needs to address why the liver responds differently from other organs or how liver-specific factors modulate general pathways.

• Single mouse strain without validation: Using only C57BL/6 mice limits translational relevance. Hepatology expects validation in multiple strains or models when claiming general mechanisms. The journal particularly scrutinizes diet-induced NASH models that don't recapitulate human disease features.

• Biomarker papers without mechanistic insight: Identifying new serum markers for liver disease isn't enough anymore. Editors want mechanistic understanding of why these markers change and how they connect to disease pathogenesis. Pure correlation studies get rejected unless they include substantial mechanistic validation.

• Overinterpreting hepatocyte cell line data: HepG2 and other immortalized hepatocyte lines have limited relevance to in vivo liver biology. Papers that draw broad conclusions about liver disease from cell line studies face immediate skepticism. You need primary hepatocytes or in vivo validation for major claims.

• Inadequate clinical context: Basic science papers that don't connect findings to human liver disease get filtered out during editorial screening. Even mechanistic studies need clear relevance to hepatology practice. Mention specific patient populations or therapeutic implications.

• Statistical power problems: Underpowered studies with n=3-4 per group don't meet Hepatology standards. Animal studies typically need n=8-10 minimum. Human studies require proper power calculations. Negative results without adequate power analysis get rejected.

• Scope creep into other organs: Papers that start with liver focus but drift into general metabolism or other organ systems lose editorial interest. Keep liver biology central throughout your story.

• Incomplete methods sections: Hepatology editors scrutinize liver-specific methodology closely. Fasting protocols for metabolic studies, hepatocyte isolation procedures, and liver histology scoring methods need complete details. Incomplete methods trigger immediate reviewer criticism.

• Weak translational bridge: Pure bench science without clinical relevance doesn't fit Hepatology's translational mission. Include discussion of how findings might impact patient care or suggest therapeutic targets. The journal wants research that advances both understanding and treatment of liver disease.

Before submitting to Hepatology, a Hepatology manuscript fit check identifies whether the package meets the editorial bar before you commit to the submission.

• Editorial screening: the editor-in-chief or associate editors first evaluate scope, quality, and likely impact. A large share of papers stop here if the fit is weak or the translational bridge is vague.

• Peer review assignment: if your paper passes screening, it moves to specialist reviewers with liver-disease expertise. Highly specialized topics can take longer simply because the reviewer pool is narrower.

• Reviewer response time: reviewer turnaround varies, and complicated translational packages can slow down because reviewers often look carefully at both the mechanistic and clinical sides of the paper.

• Editorial decision: Hepatology does not publish decision timelines or revision-outcome statistics. The Editor allows a single resubmission only after the initial disposition.

• Revision timeline: A manuscript requiring more than a single revision, or returned beyond three months of the date of the initial decision, is considered a new submission.

• Total timeline: expect a multi-stage process rather than a quick yes or no. Final acceptance often depends on how much additional support reviewers ask for.

The timeline moves faster when your methods are clear, results are straightforward, and clinical relevance is obvious. Check if your paper is ready before submitting to avoid delays from reviewer requests for additional experiments.

• Journal of Hepatology (European Association for Study of the Liver): Similar scope and quality to Hepatology. Impact factor 33.0. Slightly more European author representation. Faster publication timeline.

• Gastroenterology: Broader scope including liver, but harder to get liver papers accepted due to competition with GI tract research. JIF 25.1. Best for liver research with broader GI implications.

• Gut: Strong liver section with excellent clinical hepatology papers. JIF 25.8. More accessible than Gastroenterology for pure liver studies.

• American Journal of Transplantation: Perfect fit for liver transplantation research. JIF 8.2. Specialized audience but highly engaged readership.

• Journal of Clinical Investigation: For liver research with broad biomedical impact. JIF 13.6. Extremely selective but prestigious.

• Clinical Gastroenterology and Hepatology: Clinical focus with practice-relevant findings. JIF 16.2. Good alternative for translational liver research.

Consider journal scope carefully. Our journal selection guide helps match your liver research to the right venue based on methodology, clinical relevance, and target audience.

Before you upload, run your manuscript through a Hepatology submission readiness check to catch the issues editors filter for on first read.

For manuscripts targeting Hepatology, five patterns generate the most consistent desk rejections worth knowing before submission.

The patterns below are Manusights editorial judgment about desk-rejection risk, not triggers documented in Hepatology's submission guidelines; addressing these before submission meaningfully reduces early-rejection risk.

Hepatocyte line data without primary cell or in vivo validation

The Hepatology author guidelines ask that experiments using cell lines be replicated in more than one cell line wherever possible, and they note that Hep G2 and HuH-6 cells were derived from hepatoblastoma, so using them as models of HCC is misleading unless the study is about specific characteristics of those lines. A recurring manuscript pattern we see many desk rejections involve manuscripts that draw broad conclusions about liver disease mechanisms from HepG2 or other immortalized hepatocyte line data without primary hepatocyte validation or in vivo evidence.

Editors specifically screen for manuscripts where the biological model is appropriate for the mechanistic claim, because cell line extrapolation to hepatic disease is among the most common reviewer objections at this journal tier.

Liver study without liver-specific mechanistic contribution

We also often find many submissions study general biological pathways using hepatocytes or liver tissue as a convenient model without establishing that the mechanism is liver-specific, or without explaining how liver biology modifies the pathway relative to other organ systems. In practice, editors consistently desk-reject manuscripts where the hepatology angle is contextual rather than mechanistic, because the journal's scope requires that the liver-specific dimension be present in the data, not inferred from the disease population studied.

Biomarker paper without mechanistic connection to liver disease

A related pattern is that many submissions identify new serum or tissue markers for liver disease without demonstrating through mechanistic or functional data why those markers change and how they connect to hepatic disease pathogenesis. Editors consistently screen for manuscripts where the biomarker finding is supported by mechanistic interpretation, because pure correlation studies without biological validation have a consistently lower acceptance rate at Hepatology regardless of clinical cohort size.

Check biomarker paper without mechanistic connection to liver disease before submitting to Hepatology →

Sample size too small for the clinical liver claim made

A related pattern is that many submissions arrive with animal studies using fewer than 8-10 mice per group, or with clinical cohorts where the sample size is not justified relative to the claims being advanced about liver disease mechanisms or therapeutic relevance. In our analysis of submission difficulties at Hepatology, this pattern is most common when authors submit mechanistic liver research with sample sizes calibrated to a pilot-level threshold rather than to the evidence standards the journal applies for hepatic pathogenesis claims.

Check sample size too small for the clinical liver claim made before submitting to Hepatology →

Cover letter names the liver finding but omits the clinical payoff

A related pattern is that many submissions arrive with cover letters that describe the hepatological finding or the biological model without explaining what the results mean for hepatology practice, liver disease management, or therapeutic development. Editors explicitly consider whether the cover letter makes the translational case before routing the paper for peer review.

SciRev author-reported review times and Clarivate 2026 JCR release bibliometric data provide additional benchmarks when planning your submission timeline.

Before submitting to Hepatology, a Hepatology submission readiness check identifies whether your translational framing, mechanistic evidence, and liver-specific relevance meet the editorial bar before you commit to the submission.

Or see example reports before you finalize.

Check cover letter names the liver finding but omits the clinical payoff before submitting to Hepatology →

• Hepatology submission process

• How to Avoid Desk Rejection at Hepatology

• Is Hepatology a Good Journal?

• Gut vs Hepatology

Hepatology fit weakens when a general metabolic, inflammatory, or oncology result is relabeled as liver research. Use this trace to show why the conclusion is specifically hepatic and clinically or biologically meaningful.

Align this trace with the abstract verbs, figure order, reporting checklist, and cover letter. A narrower liver-specific claim with clear support is stronger than a broad clinical promise built on one indirect link.

Evidence reviewed 2026-10-09: We rechecked the current official sources listed below. Population, endpoint, comparator, effect, harms, uncertainty, and transfer boundary should survive every submission artifact.